Abstract
Background: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody that has demonstrated a manageable safety profile in patients with relapsed or refractory (R/R) non-Hodgkin lymphoma in a pivotal phase II study (GO29781; NCT02500407). Rapid identification and appropriate management of adverse events (AEs) are key for patients receiving mosunetuzumab, and advanced practice providers (APPs) play a vital role. Methods: Six APPs were surveyed, including nurse practitioners, a research nurse, clinical pharmacists, and physician assistants, from four US academic centers involved in the phase II GO29781 study of mosunetuzumab administered intravenously in patients with R/R follicular lymphoma. Advanced practice providers provided their perspectives and experiences on their roles in the education of staff and patients, and in the monitoring and management of AEs associated with mosunetuzumab treatment. Results: APPs provided education to staff and patients around the signs and symptoms of potential AEs as well as mosunetuzumab’s mechanism of action, route of administration, and dosing schedule. They were involved in monitoring patients for AEs using clinical assessments and laboratory tests and were responsible for managing AEs, ordering necessary interventions, deciding when to interrupt treatment, clearing patients for their next dose, and advising the wider medical team on steps for patient management. Conclusions: APPs play a key role as part of a multidisciplinary team to ensure the safety and comfort of patients receiving mosunetuzumab in the outpatient setting. The APP experiences presented here may be used to inform future clinical practice and care coordination for mosunetuzumab treatment.
References
Bannerji, R., Arnason, J. E., Advani, R. H., Brown, J. R., Allan, J. N., Ansell, S. M.,…Topp, M. S. (2022). Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. The Lancet Haematology, 9(5), e327–e339. https://doi.org/10.1016/s2352-3026(22)00072-2
Batlevi, C. L., Sha, F., Alperovich, A., Ni, A., Smith, K., Ying, Z.,…Younes, A. (2020). Follicular lymphoma in the modern era: Survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer Journal, 10(7), 74. https://doi.org/10.1038/s41408-020-00340-z
Budde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P.,…Bartlett, N. L. (2022). Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. Lancet Oncology, 23(8), 1055–1065. https://doi.org/10.1016/s1470-2045(22)00335-7
Crombie, J. L., Graff, T., Falchi, L., Karimi, Y. H., Bannerji, R., Nastoupil, L.,…Dickinson, M. (2024). Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood, 143(16), 1565–1575. https://doi.org/10.1182/blood.2023022432
Dickinson, M. J., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G.,…Hutchings, M. (2022). Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med, 387(24), 2220–2231. https://doi.org/10.1056/NEJMoa2206913
European Medicines Agency. (2025). Summary of product characteristics: Lunsumio 1 mg concetnrate for solution for infusion; Lunsumio 30 mg concentrate for solution for infusion. https://www.ema.europa.eu/en/documents/product-information/lunsumio-epar-product-information_en.pdf
F. Hoffmann-La Roche Ltd. (2025). European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma. https://www.roche.com/media/releases/med-cor-2025-11-19
Fowler, N. H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J.,…Thieblemont, C. (2022). Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial. Nature Medicine, 28(2), 325–332. https://doi.org/10.1038/s41591-021-01622-0
Freedman, A., & Jacobsen, E. (2020). Follicular lymphoma: 2020 update on diagnosis and management. American Journal of Hematology, 95(3), 316–327. https://doi.org/10.1002/ajh.25696
Ghione, P., Palomba, M. L., Ghesquieres, H., Bobillo, S., Patel, A. R., Nahas, M.,…Gribben, J. (2023). Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: Results from the international SCHOLAR-5 study. Haematologica, 108(3), 822–832. https://doi.org/10.3324/haematol.2022.281421
Hutchings, M., Morschhauser, F., Iacoboni, G., Carlo-Stella, C., Offner, F. C., Sureda, A.,…Dickinson, M. J. (2021a). Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. Journal of Clinical Oncology, 39(18), 1959–1970. https://doi.org/10.1200/jco.20.03175
Hutchings, M., Mous, R., Clausen, M. R., Johnson, P., Linton, K. M., Chamuleau, M. E. D.,…Lugtenburg, P. J. (2021b). Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet (London, England), 398(10306), 1157–1169. https://doi.org/10.1016/s0140-6736(21)00889-8
Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G.,…Neelapu, S. S. (2022). Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. Lancet Oncology, 23(1), 91–103. https://doi.org/10.1016/S1470-2045(21)00591-X
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M.,…Mackall, C. L. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124(2), 188–195. https://doi.org/10.1182/blood-2014-05-552729
Matasar, M., Bartlett, N. L., Shadman, M., Budde, L. E., Flinn, I., Gregory, G. P.,…Assouline, S. (2024). Mosunetuzumab safety profile in patients with relapsed/refractory B-cell non-hodgkin lymphoma: clinical management experience from a pivotal phase I/II trial. Clinical Lymphoma, Myeloma & Leukemia, 24(4), 240–253. https://doi.org/10.1016/j.clml.2023.12.005
Rivas-Delgado, A., Magnano, L., Moreno-Velázquez, M., García, O., Nadeu, F., Mozas, P.,…López-Guillermo, A. (2019). Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. British Journal of Haematology, 184(5), 753–759. https://doi.org/10.1111/bjh.15708
Schram, A. M., & Berliner, N. (2015). How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood, 125(19), 2908–2914. https://doi.org/10.1182/blood-2015-01-551622
Shadman, M., Bartlett, N. L., Matasar, M., Schuster, S. J., Assouline, S. E., Sehn, L. H.,…Budde, L. E. (2024). Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study. Blood, 144(Suppl. 1), 4407. https://doi.org/10.1182/blood-2024-197897
Sun, L. L., Ellerman, D., Mathieu, M., Hristopoulos, M., Chen, X., Li, Y.,…Ebens, A. J. (2015). Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Science Translational Medicine, 7(287), 287ra270. https://doi.org/10.1126/scitranslmed.aaa4802
US Food and Drug Administration. (2022). Prescribing information: Lunsumio™ (mosunetuzumab-axgb) injection, of intravenous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf
US Food and Drug Administration. (2025a). Prescribing information: Lunsumio VELO™ (mosunetuzumab-axgb) injection, for subcutaneous use. https://www.gene.com/download/pdf/lunsumio_velo_prescribing.pdf
US Food and Drug Administration. (2025b). BREYANZI® US Prescribing Information. https://www.fda.gov/media/145711/download
Vallurupalli, M., & Berliner, N. (2019). Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood, 134(21), 1783–1786. https://doi.org/10.1182/blood.2019002289
